ABSTRACT
Disruption of the insulin receptor substrate-2 was shown to cause type 2 diabetes in mice. This could be largely attributed to abnormal beta-cell development. In humans, a prevalent polymorphism in insulin receptor substrate-2 (Gly1057Asp) was not found be associated with type 2 diabetes in linkage and association studies. We tested the hypothesis that an extreme challenge of the beta cell might reveal subtle abnormalities in carriers of this polymorphism undetected by conventional insulin secretion tests. Therefore, in addition to assessing beta-cell function by oral glucose tolerance testing (n = 318, normal glucose tolerance), we measured the secretory response to maximal stimulation by hyperglycemia (10 mM), glucagon-like peptide-1, and arginine administered in an additive fashion (n = 77, nondiabetic). The allelic frequency of the Asp allele was approximately 37%. Neither the beta-cell function indices from the oral glucose tolerance test nor the secretory response during the hyperglycemic clamp differed measurably between carriers and controls. Moreover, maximal plasma C-peptide concentrations in response to the combined glucose, glucagon-like peptide-1, and arginine stimulus was not different between Gly/Gly (10,745 +/- 1,186 pmol/liter) and X/Asp (10,800 +/- 490 pmol/liter, P = 0.99). In conclusion, our findings strongly suggest that the Gly1057Asp polymorphism in insulin receptor substrate-2 is not associated with beta-cell dysfunction. The normal maximal insulin secretory response makes it unlikely that this common polymorphism results in abnormal beta-cell development.
Subject(s)
Insulin/metabolism , Islets of Langerhans/physiology , Phosphoproteins/genetics , Polymorphism, Genetic , Adult , Female , Humans , Insulin Receptor Substrate Proteins , Insulin Secretion , Intracellular Signaling Peptides and Proteins , MaleABSTRACT
The Gly972Arg polymorphism in the insulin receptor substrate (IRS)-1 was found in some studies to have a higher prevalence in type 2 diabetic subjects than in control subjects. Previously, transfection of IRS-1 with this polymorphism into insulin-secreting cells resulted in a marked reduction of glucose-stimulated insulin secretion compared with the wild-type transfected cells. In the present study, we compared insulin secretion in well-matched normal glucose-tolerant subjects with and without this polymorphism. Several validated indexes of beta-cell function from the oral glucose tolerance test were significantly lower in X/Arg (n = 31) compared with Gly/Gly (n = 181) (P between 0.002 and 0.05), whereas insulin sensitivity (measured with a euglycemic clamp) was not different. During a modified hyperglycemic clamp, insulin secretion rates were significantly lower in Gly/Arg (n = 8) compared with Gly/Gly (n = 36) during the first phase (1,711+/-142 vs. 3,014+/-328 pmol/min, P = 0.05) and after maximal stimulation with arginine (5,340+/-639 vs. 9,075+/-722 pmol/min, P = 0.03). In summary, our results suggest that the Gly972Arg polymorphism in IRS-1 is associated with decreased insulin secretion in response to glucose but not with insulin sensitivity. It is possible that this polymorphism causes insulin resistance at the level of the beta-cell and contributes to the polygenic etiology of type 2 diabetes.
Subject(s)
Genetic Variation/physiology , Glucose/physiology , Insulin/metabolism , Phosphoproteins/genetics , Polymorphism, Genetic/physiology , Arginine/pharmacology , Glucose Tolerance Test , Humans , Insulin Receptor Substrate Proteins , Insulin Secretion , Islets of Langerhans/metabolism , Reference ValuesABSTRACT
Consumption of alcohol and illegal drugs is a widespread phenomenon in Germany. The first contact with drugs usually takes place during adolescence. Experimental use of drugs is an integral part of personal development during adolescence. The aim of this paper is to analyse the supporting infrastucture available to adolescents who are at risk of substance abuse, with special focus on its structural deficits. In addition to epidemiological data for alcohol and illegal drugs, the professional support system is described. The support system for adolescents who have already begun with experimental usage with drugs is analysed on the basis of three interview studies: 1) professionals from support and care institutions, 2) adolescents with health hazardous drug consumption patterns, and 3) those who seek the services of health care institutions. The results show that the existing treatment does not meet the needs and demands of adolescents in most cases, because the professional support institutions cannot cope with the real context of adolescent drug abuse. Recommendations for improvements of the support institutions are finally discussed.